person · Reporting owner

YANG MICHAEL J.

Disclosed activity across 4 companies

Tapewire entity: 32407
SEC CIK: 0001702283

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ACADIA PHARMACEUTICALS INCACAD · Entity 3913	EVP and CCO	January 06, 2021	January 09, 2021
IONIS PHARMACEUTICALS INCIONS · Entity 1182	Director	July 01, 2026	July 06, 2026
Pacira BioSciences, Inc.PCRX · Entity 4928	Director	June 10, 2026	June 13, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ACADIA PHARMACEUTICALS INC

Report date January 06, 2021 · Filed January 09, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,059	Ending reported balance After 2021-01-06 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2021-01-06 · Exercise / conversion · Acquired 2,722 · Balance 9,179 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2021-01-06 · Sale · Disposed 1,120 · Balance 8,059 F2: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	8,167	Reported balance After 2021-01-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-01-06 · Exercise / conversion · Disposed 2,722 · Balance 8,167 F3: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: The restricted stock units vest in four equal annual installments beginning January 6, 2021.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F2: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

F3: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F4: The restricted stock units vest in four equal annual installments beginning January 6, 2021.

IONIS PHARMACEUTICALS INC

Report date July 01, 2026 · Filed July 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $79.19 · Expires 2036-06-30	Direct	5,369	Reported balance After 2026-07-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-07-01 · Grant · Acquired 5,369 · Balance 5,369 F1: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F2: Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	9,451	Reported balance After 2026-07-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-07-01 · Grant · Acquired 2,301 · Balance 9,451 F3: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F4: Grant of Restricted Stock Unit award on July 1, 2026 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the fifth anniversary of the vesting date, the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 1, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F2: Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026.

F3: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F4: Grant of Restricted Stock Unit award on July 1, 2026 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the fifth anniversary of the vesting date, the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 1, 2026.

Pacira BioSciences, Inc.

Report date June 10, 2026 · Filed June 13, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	19,798	Reported balance After 2026-06-10 transaction · row 1 1 source row Row 1 · 2026-06-10 · Grant · Acquired 6,405 · Balance 19,798 F1: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.42 · Expires 2036-06-10	Direct	10,891	Reported balance After 2026-06-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-10 · Grant · Acquired 10,891 · Balance 10,891 F2: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

F2: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AKCEA THERAPEUTICS, INC.

Report date October 12, 2020 · Filed October 13, 2020

Section 16 reporting ended · disclosed 2020-10-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.14 · Expires 2030-04-12	Direct	0	Reported balance After 2020-10-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-10-12 · Disposition to issuer · Disposed 26,400 · Balance 0 F1: This option, which provided for vesting of the shares on April 13, 2021, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $53,064.00, representing the difference between the exercise price of the option and the acquisition price of $18.15.

Filing footnotes · ownership attribution and instrument terms

F1: This option, which provided for vesting of the shares on April 13, 2021, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $53,064.00, representing the difference between the exercise price of the option and the acquisition price of $18.15.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 01, 2026 Filed Jul 6, 2026 22:50 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantRestricted Stock Unit · Derivative	2,301	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000874015-26-000232 · edgardoc.xml · derivative · entry 2 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,451 Underlying: Common Stock · 2,301 shares Expires not disclosed F3 · derivative.exercise_price: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F4 · derivative.exercise_date: Grant of Restricted Stock Unit award on July 1, 2026 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the fifth anniversary of the vesting date, the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 1, 2026. F4 · derivative.expiration_date: Grant of Restricted Stock Unit award on July 1, 2026 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the fifth anniversary of the vesting date, the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 1, 2026. Read SEC document
July 01, 2026 Filed Jul 6, 2026 22:50 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantNon-Qualified Stock Option (right to buy) · Derivative	5,369	$0.00 Strike: $79.19	$0.00	Disclosure SEC source: 0000874015-26-000232 · edgardoc.xml · derivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,369 Underlying: Common Stock · 5,369 shares Expires 2036-06-30 F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F2 · derivative.exercise_date: Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026. F2 · derivative.expiration_date: Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026. Read SEC document
June 10, 2026 Filed Jun 13, 2026 01:07 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantStock Option (Right to Buy) · Derivative	10,891	$0.00 Strike: $23.42	$0.00	Disclosure SEC source: 0001628280-26-043005 · wk-form4_1781312832.xml · derivative · entry 2 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,891 Underlying: Common Stock · 10,891 shares Expires 2036-06-10 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document
June 10, 2026 Filed Jun 13, 2026 01:07 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantCommon Stock	6,405	$0.00	$0.00	Disclosure SEC source: 0001628280-26-043005 · wk-form4_1781312832.xml · nonDerivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,798 F1 · shares: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document
January 15, 2026 Filed Jan 21, 2026 01:21 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionRestricted Stock Unit · Derivative	1,930	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000874015-26-000073 · edgardoc.xml · derivative · entry 2 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,150 Underlying: Common Stock · 1,930 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in three equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in three equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document
January 15, 2026 Filed Jan 21, 2026 01:21 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	1,930	$0.00	$0.00	Disclosure SEC source: 0000874015-26-000073 · edgardoc.xml · nonDerivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,940 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document
July 15, 2025 Filed Jul 17, 2025 20:54 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionRestricted Stock Unit · Derivative	4,079	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000874015-25-000161 · edgardoc.xml · derivative · entry 2 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,080 Underlying: Common Stock · 4,079 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document
July 15, 2025 Filed Jul 17, 2025 20:54 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	4,079	$0.00	$0.00	Disclosure SEC source: 0000874015-25-000161 · edgardoc.xml · nonDerivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document
July 01, 2025 Filed Jul 2, 2025 20:53 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantRestricted Stock Unit · Derivative	5,220	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000874015-25-000144 · edgardoc.xml · derivative · entry 2 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,159 Underlying: Common Stock · 5,220 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F4 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025. F4 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025. Read SEC document
July 01, 2025 Filed Jul 2, 2025 20:53 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantNon-Qualified Stock Option (right to buy) · Derivative	11,518	$0.00 Strike: $39.94	$0.00	Disclosure SEC source: 0000874015-25-000144 · edgardoc.xml · derivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,518 Underlying: Common Stock · 11,518 shares Expires 2035-06-30 F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F2 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025. F2 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025. Read SEC document
June 11, 2025 Filed Jun 13, 2025 20:17 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantStock Option (Right to Buy) · Derivative	11,279	$0.00 Strike: $24.34	$0.00	Disclosure SEC source: 0001396814-25-000083 · wk-form4_1749845868.xml · derivative · entry 2 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,279 Underlying: Common Stock · 11,279 shares Expires 2035-06-11 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on June 11, 2026, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document
June 11, 2025 Filed Jun 13, 2025 20:17 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantCommon Stock	6,163	$0.00	$0.00	Disclosure SEC source: 0001396814-25-000083 · wk-form4_1749845868.xml · nonDerivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,393 F1 · shares: Represents restricted stock units that vest on June 11, 2026, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document
January 15, 2025 Filed Jan 18, 2025 00:41 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionRestricted Stock Unit · Derivative	1,931	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000874015-25-000066 · edgardoc.xml · derivative · entry 2 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,939 Underlying: Common Stock · 1,931 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in three equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in three equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document
January 15, 2025 Filed Jan 18, 2025 00:41 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	Exercise / conversionCommon Stock	1,931	$0.00	$0.00	Disclosure SEC source: 0000874015-25-000066 · edgardoc.xml · nonDerivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document
August 14, 2024 Filed Aug 14, 2024 20:35 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	PurchaseCommon Stock	2,000	$12.90	$25,800.00	Disclosure SEC source: 0001396814-24-000114 · wk-form4_1723667702.xml · nonDerivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,230 Read SEC document
July 01, 2024 Filed Jul 3, 2024 19:13 UTC Amendment	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantRestricted Stock Unit · Derivative	4,079	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000874015-24-000169 · edgardoc.xml · derivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,870 Underlying: Common Stock · 4,079 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F2 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2024 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F3 · derivative.exercise_date: Grant on July 1, 2024 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2024. F3 · derivative.expiration_date: Grant on July 1, 2024 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2024. Read SEC document
July 01, 2024 Filed Jul 3, 2024 18:48 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantNon-Qualified Stock Option (right to buy) · Derivative	10,111	$0.00 Strike: $47.11	$0.00	Disclosure SEC source: 0000874015-24-000167 · edgardoc.xml · derivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,111 Underlying: Common Stock · 10,111 shares Expires 2034-06-30 F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2024 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. F2 · derivative.exercise_date: Grant on July 1, 2024 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2024. F2 · derivative.expiration_date: Grant on July 1, 2024 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2024. Read SEC document
June 12, 2024 Filed Jun 13, 2024 22:13 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantStock Option (Right to Buy) · Derivative	12,179	$0.00 Strike: $28.68	$0.00	Disclosure SEC source: 0001396814-24-000080 · wk-form4_1718316831.xml · derivative · entry 2 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,179 Underlying: Common Stock · 12,179 shares Expires 2034-06-12 Read SEC document
June 12, 2024 Filed Jun 13, 2024 22:13 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantCommon Stock	5,230	$0.00	$0.00	Disclosure SEC source: 0001396814-24-000080 · wk-form4_1718316831.xml · nonDerivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,230 F1 · shares: Represents restricted stock units that vest on June 12, 2025, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document
January 15, 2024 Filed Jan 18, 2024 01:50 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantRestricted Stock Unit · Derivative	5,791	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000874015-24-000057 · edgardoc.xml · derivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,791 Underlying: Common Stock · 5,791 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F2 · derivative.exercise_date: Grant on January 15, 2024 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in three equal annual installments, the first installment vesting on January 15, 2025. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2027. The RSU is vested as to 0 shares on January 15, 2024. F2 · derivative.expiration_date: Grant on January 15, 2024 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in three equal annual installments, the first installment vesting on January 15, 2025. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2027. The RSU is vested as to 0 shares on January 15, 2024. Read SEC document
December 14, 2023 Filed Dec 18, 2023 21:58 UTC	IONIS PHARMACEUTICALS INC IONS · Entity 1182	GrantNon-Qualified Stock Option (right to buy) · Derivative	12,356	$0.00 Strike: $49.82	$0.00	Disclosure SEC source: 0000874015-23-000230 · edgardoc.xml · derivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,356 Underlying: Common Stock · 12,356 shares Expires 2033-12-14 F1 · derivative.exercise_date: Grant of 12/14/2023 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in three equal annual installments, the first installment vesting on 12/14/2024. The option shall be fully vested and exercisable on 12/14/2026. The stock option was exercisable as to 0 shares on 12/14/2023. F1 · derivative.expiration_date: Grant of 12/14/2023 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in three equal annual installments, the first installment vesting on 12/14/2024. The option shall be fully vested and exercisable on 12/14/2026. The stock option was exercisable as to 0 shares on 12/14/2023. Read SEC document
October 06, 2023 Filed Oct 11, 2023 20:46 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	GrantStock Option (Right to Buy) · Derivative	30,967	$0.00 Strike: $29.80	$0.00	Disclosure SEC source: 0001396814-23-000072 · wk-form4_1697057204.xml · derivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,967 Underlying: Common Stock · 30,967 shares Expires 2033-10-06 F1 · derivative.exercise_date: The options vest in 36 equal successive monthly installments over the 36-month period following the date of grant, subject to the reporting person's continued service as a director. Read SEC document
January 06, 2021 Filed Jan 9, 2021 00:31 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionRestricted Stock Units · Derivative	2,722	$0.00	$0.00	Disclosure SEC source: 0001209191-21-002836 · doc4.xml · derivative · entry 3 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,167 Underlying: Common Stock · 2,722 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. Read SEC document
January 06, 2021 Filed Jan 9, 2021 00:31 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	1,120	$53.34	$59,740.80	Disclosure SEC source: 0001209191-21-002836 · doc4.xml · nonDerivative · entry 2 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,059 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document
January 06, 2021 Filed Jan 9, 2021 00:31 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	2,722	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-002836 · doc4.xml · nonDerivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
October 16, 2020 Filed Oct 19, 2020 21:27 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	1,247	$42.56	$53,072.32	Disclosure SEC source: 0001209191-20-055317 · doc4.xml · nonDerivative · entry 2 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,457 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document
October 15, 2020 Filed Oct 19, 2020 21:27 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionRestricted Stock Units · Derivative	2,500	$0.00	$0.00	Disclosure SEC source: 0001209191-20-055317 · doc4.xml · derivative · entry 3 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 10/15/19. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 10/15/19. Read SEC document
October 15, 2020 Filed Oct 19, 2020 21:27 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	2,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055317 · doc4.xml · nonDerivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
October 12, 2020 Filed Oct 13, 2020 15:45 UTC	AKCEA THERAPEUTICS, INC. AKCA · Entity 145982	Disposition to issuerStock Option (right to buy) · Derivative	26,400	$2.01 Strike: $16.14	$53,064.00	Disclosure SEC source: 0001209191-20-054611 · doc4.xml · derivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,400 shares Expires 2030-04-12 F1 · derivative.exercise_date: This option, which provided for vesting of the shares on April 13, 2021, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $53,064.00, representing the difference between the exercise price of the option and the acquisition price of $18.15. Read SEC document
July 07, 2020 Filed Jul 9, 2020 22:26 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionStock Option (Right to Buy) · Derivative	14,750	$0.00 Strike: $25.12	$0.00	Disclosure SEC source: 0001209191-20-042022 · doc4.xml · derivative · entry 8 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,292 Underlying: Common Stock · 14,750 shares Expires 2029-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the 59,042 shares originally subject to the Stock Option vested and became exercisable on April 29, 2020. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document
July 07, 2020 Filed Jul 9, 2020 22:26 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionStock Option (Right to Buy) · Derivative	5,000	$0.00 Strike: $21.28	$0.00	Disclosure SEC source: 0001209191-20-042022 · doc4.xml · derivative · entry 7 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 5,000 shares Expires 2028-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the 40,000 shares originally subject to the Stock Option vested and became exercisable on October 15, 2019. The remaining shares vest and become excercisable thereafter in 36 equal monthly installments. Read SEC document
July 07, 2020 Filed Jul 9, 2020 22:26 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionStock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $19.98	$0.00	Disclosure SEC source: 0001209191-20-042022 · doc4.xml · derivative · entry 6 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,000 Underlying: Common Stock · 7,500 shares Expires 2028-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the 600,000 shares originally subject to the Stock Option vested and became exercisable on April 18, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments Read SEC document
July 07, 2020 Filed Jul 9, 2020 22:26 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	11,100	$56.54	$627,574.02	Disclosure SEC source: 0001209191-20-042022 · doc4.xml · nonDerivative · entry 5 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to an amended Rule 10b5-1 stock sale plan dated May 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.395 to $56.685, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
July 07, 2020 Filed Jul 9, 2020 22:26 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	16,150	$56.05	$905,212.35	Disclosure SEC source: 0001209191-20-042022 · doc4.xml · nonDerivative · entry 4 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,304 F1 · kind: The sales reported in this Form 4 were effected pursuant to an amended Rule 10b5-1 stock sale plan dated May 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.39 to $56.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
July 07, 2020 Filed Jul 9, 2020 22:26 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	14,750	$25.12	$370,520.00	Disclosure SEC source: 0001209191-20-042022 · doc4.xml · nonDerivative · entry 3 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,454 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 07, 2020 Filed Jul 9, 2020 22:26 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	5,000	$21.28	$106,400.00	Disclosure SEC source: 0001209191-20-042022 · doc4.xml · nonDerivative · entry 2 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 07, 2020 Filed Jul 9, 2020 22:26 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	7,500	$19.98	$149,850.00	Disclosure SEC source: 0001209191-20-042022 · doc4.xml · nonDerivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 30, 2020 Filed May 1, 2020 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	1,501	$49.21	$73,864.21	Disclosure SEC source: 0001209191-20-026618 · doc4.xml · nonDerivative · entry 2 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,204 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document
April 29, 2020 Filed May 1, 2020 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionRestricted Stock Units · Derivative	4,206	$0.00	$0.00	Disclosure SEC source: 0001209191-20-026618 · doc4.xml · derivative · entry 3 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,621 Underlying: Common Stock · 4,206 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 4/29/2020. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 4/29/2020. Read SEC document
April 29, 2020 Filed May 1, 2020 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	4,206	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-026618 · doc4.xml · nonDerivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. Read SEC document
April 13, 2020 Filed Apr 15, 2020 17:13 UTC	AKCEA THERAPEUTICS, INC. AKCA · Entity 145982	GrantStock Option (right to buy) · Derivative	26,400	$0.00 Strike: $16.14	$0.00	Disclosure SEC source: 0001209191-20-024503 · doc4.xml · derivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2030-04-12 F1 · derivative.exercise_date: The shares vest on the 12-month anniversary of the date of grant. Read SEC document
January 06, 2020 Filed Jan 8, 2020 23:08 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantRestricted Stock Units · Derivative	10,889	$0.00	$0.00	Disclosure SEC source: 0001209191-20-002604 · doc4.xml · derivative · entry 2 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,889 Underlying: Common Stock · 10,889 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. Read SEC document
January 06, 2020 Filed Jan 8, 2020 23:08 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantStock Options (Right to Buy) · Derivative	39,516	$0.00 Strike: $42.81	$0.00	Disclosure SEC source: 0001209191-20-002604 · doc4.xml · derivative · entry 1 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,516 Underlying: Common Stock · 39,516 shares Expires 2030-01-06 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on January 6, 2021. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document
December 12, 2019 Filed Dec 13, 2019 22:35 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionStock Option (Right to Buy) · Derivative	72,979	$0.00 Strike: $35.86	$0.00	Disclosure SEC source: 0001209191-19-060476 · doc4.xml · derivative · entry 8 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,500 Underlying: Common Stock · 72,979 shares Expires 2027-03-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the 400,000 shares originally subject to the stock option vested and became exercisable on March 29, 2018. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document
December 12, 2019 Filed Dec 13, 2019 22:35 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $21.28	$0.00	Disclosure SEC source: 0001209191-19-060476 · doc4.xml · derivative · entry 7 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 10,000 shares Expires 2028-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the 40,000 shares originally subject to the Stock Option vested and became exercisable on October 15, 2019. The remaining shares vest and become excercisable thereafter in 36 equal monthly installments. Read SEC document
December 12, 2019 Filed Dec 13, 2019 22:35 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionStock Option (Right to Buy) · Derivative	22,500	$0.00 Strike: $19.98	$0.00	Disclosure SEC source: 0001209191-19-060476 · doc4.xml · derivative · entry 6 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 577,500 Underlying: Common Stock · 22,500 shares Expires 2028-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the 600,000 shares originally subject to the Stock Option vested and became exercisable on April 18, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments Read SEC document
December 12, 2019 Filed Dec 13, 2019 22:35 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	5,032	$43.74	$220,074.52	Disclosure SEC source: 0001209191-19-060476 · doc4.xml · nonDerivative · entry 5 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,499 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.67 to $43.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
December 12, 2019 Filed Dec 13, 2019 22:35 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	100,447	$44.49	$4,469,188.37	Disclosure SEC source: 0001209191-19-060476 · doc4.xml · nonDerivative · entry 4 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,531 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.755 to $44.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
December 12, 2019 Filed Dec 13, 2019 22:35 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	72,979	$35.86	$2,617,026.94	Disclosure SEC source: 0001209191-19-060476 · doc4.xml · nonDerivative · entry 3 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 12, 2019 Filed Dec 13, 2019 22:35 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	10,000	$21.28	$212,800.00	Disclosure SEC source: 0001209191-19-060476 · doc4.xml · nonDerivative · entry 2 YANG MICHAEL J. · CIK 0001702283 · EVP and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.